FDA Approves Wegovy HD 7.2 mg, Delivering 20.7% Mean Weight Loss

More like this

• Health10/04/2026@HealthDesk

  FDA Approves Novo Nordisk's Wegovy Pill, the First Oral GLP-1 for Weight Loss

  Novo Allé 1, Bagsværd, DenmarkNovo Nordisk

  

  Starts 12/22/2025CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better287 days agoNovo's announcement is dated "Bagsværd, Denmark, 22 December 2025"; its full-year report states "On 22 December, the US FDA approved" the pill; Fox 32 published 2025-12-22 and PharmExec^[3] 2025-12-23.

  On 22 December 2025 the US FDA approved the once-daily Wegovy pill (oral semaglutide 25 mg), the first oral GLP-1 for weight management, which showed 16.6% mean weight loss in the OASIS 4 trial.

  0.82

  00
• Health09/20/2026@TechDesk

  Lilly's Foundayo (Orforglipron) Weight-Loss Pill Approved by FDA

  Indianapolis, IndianaEli Lilly

  

  Starts 04/01/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better187 days agoLilly^[3] and the FDA^[4] approval letter date the approval April 1, 2026.

  The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.

  0.73

  00
• Health09/23/2026@HealthDesk

  FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor

  1360 South Loop Road, Alameda, Alameda County, California, 94502, United StatesAbbott Laboratories

  

  Starts 08/25/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better41 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.

  The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.

  0.70

  00
• Health09/20/2026@HealthDesk

  Enicepatide's Phase 3 Trial in Obesity or Overweight Reads Out

  RocheBasel, Canton of Basel-Stadt, Switzerland

  Starts 07/24/2028ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 1.8 yearsClinicalTrials.gov^[1] lists 2028-07-24 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

  0.70

  10
• Health10/04/2026@HealthDesk

  FDA Approves Merck's Lipfendra, the First Oral PCSK9 Inhibitor

  126 East Lincoln Avenue, Rahway, New Jersey, United StatesMerck & Co.

  

  Starts 07/16/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better81 days agoMerck's^[1][2] news release is dated July 16, 2026 and says the FDA 'has approved LIPFENDRA (enlicitide) tablets 20 mg'; Practical Neurology^[4] and the Family Heart^[5] Foundation report the same.

  On 16 July 2026 the FDA approved Merck's Lipfendra (enlicitide), a once-daily 20 mg tablet and the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia.

  0.70

  00
• Health09/23/2026@HealthDesk

  Lilly Submits Retatrutide to the FDA for Approval

  Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly

  

  Starts 03/31/2027ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins3 months late77% CONFIDENCEOverall confidence: 77%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or betterin 177 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]

  Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.

  0.69

  10
• Health10/04/2026@HealthDesk

  FDA Approves GSK's Blenrep for Relapsed Multiple Myeloma

  GSK House, 980 Great West Road, Brentford, United KingdomGSK

  

  Starts 10/23/2025CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins78% CONFIDENCEOverall confidence: 78%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better347 days agoGSK's^[1] press release states the FDA approval; the 23 October 2025 date is given by Pharmaceutical Executive's 24 October article and by a search summary of GSK's announcement, and the PharmaLetter^[3] calls it a re-approval.

  On 23 October 2025 the US FDA approved Blenrep with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior lines of therapy.

  0.68

  00
• Health10/04/2026@HealthDesk

  MariTide Phase 2: Up to 20% Weight Loss at 52 Weeks

  One Amgen Center Drive, Thousand Oaks, California, United StatesAmgen

  

  Starts 11/26/2024CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins88% CONFIDENCEOverall confidence: 88%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better1.9 years agoAmgen's^[1] release is datelined Thousand Oaks, Nov. 26, 2024; ConsultantLive^[4] published its report on 26 November 2024.

  On 26 November 2024 Amgen reported 52-week Phase 2 data for its monthly obesity candidate MariTide, with up to about 20% average weight loss without a plateau, and announced the MARITIME Phase 3 program.

  0.68

  00
• Health09/23/2026@HealthDesk

  Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial

  Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United StatesEli Lilly

  

  Starts 05/21/2026CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better137 days agoLilly's release is datelined "INDIANAPOLIS, May 21, 2026" and says the company "today announced positive topline results from TRIUMPH-1".^[1]

  People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.

  0.68

  10
• Health09/20/2026@HealthDesk

  Elecoglipron's Phase 3 Trial in Weight Management Reads Out

  AstraZenecaCambridge, United Kingdom

  Starts 07/31/2028ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 1.8 yearsClinicalTrials.gov^[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

  0.67

  10
• Health09/20/2026@HealthDesk

  AZD6234's Phase 3 Trial in Obesity or Overweight Reads Out

  AstraZenecaCambridge, United Kingdom

  Starts 08/11/2028ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 1.8 yearsClinicalTrials.gov^[1] lists 2028-08-11 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity.

  0.67

  00
• Health09/20/2026@HealthDesk

  Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out

  AstraZenecaCambridge, United Kingdom

  Starts 07/05/2028ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 1.8 yearsClinicalTrials.gov^[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

  AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

  0.67

  00